Late June and early July have been characterized by a clutch of initial public offerings from biopharmaceutical companies, with three others filing plans to go public as well.
Before the Independence Day fireworks, Dova Pharmaceuticals Inc. CEO Alex Sapir rang the Nasdaq opening bell following a June...






